Surgery Partners Analyst Price Targets - Benzinga

Surgery Partners Inc

SGRYNASDAQ

Trade with Public

Trade with Public

$23.16

0.030.13%

Últ. Act.: Nov 4, 4:19 PM

Panorámica general Noticias Previsión de beneficios EventosPrecios objetivoFinanzas Sentimiento Propiedad Comparar Opciones Informe de acciones

Surgery Partners Analyst Price Targets

Wall Street analyst price targets and consensus rating for Surgery Partners (SGRY).

Price Target Range — 12 Quarters

Analyst Consensus — 10 Analysts

7Buy

3Hold

Consensus RatingOutperform# Analysts10Avg. Consensus PT$24Upside to Avg. PT+3.4%

Rating Trend — Last 9 Months

Recent Analyst Actions

Ver todas las valoraciones →

Date	Firm	Analyst	Action	Rating Change	Price Target
Oct 28, 2026	UBS	A.J. Rice	Downgrade	Buy→Neutral	$21→$24
Oct 27, 2026	StoneX	Bill Sutherland	Downgrade	Buy→Hold	—
Sep 30, 2026	RBC Capital	Ben Hendrix	Maintained	Outperform	$19
Sep 18, 2026	TD Cowen	Ryan Langston	Maintained	Buy	$19
Sep 14, 2026	JP Morgan	Benjamin Rossi	PT Raise	Neutral	$14→$15
Aug 11, 2026	TD Cowen	Ryan Langston	PT Raise	Buy	$17→$19
Aug 11, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$20→$19
Aug 11, 2026	Cantor Fitzgerald	Sarah James	Maintained	Overweight	$18
Mar 5, 2026	TD Cowen	Ryan Langston	PT Cut	Buy	$28→$20
Mar 5, 2026	UBS	A.J. Rice	PT Cut	Buy	$29→$21
Mar 5, 2026	Mizuho	Ann Hynes	PT Cut	Outperform	$19→$17
Mar 4, 2026	RBC Capital	Ben Hendrix	PT Cut	Outperform	$31→$20
Mar 3, 2026	Barclays	Andrew Mok	PT Cut	Equal-Weight	$18→$14
Dec 18, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$22→$19
Nov 24, 2025	JP Morgan	Benjamin Rossi	PT Cut	Neutral	$27→$20
Nov 21, 2025	Barclays	Andrew Mok	PT Cut	Equal-Weight	$24→$18
Nov 17, 2025	Mizuho	Ann Hynes	PT Cut	Outperform	$28→$22
Nov 13, 2025	UBS	A.J. Rice	PT Cut	Buy	$34→$29
Nov 11, 2025	RBC Capital	Ben Hendrix	PT Cut	Outperform	$35→$31
Nov 11, 2025	Benchmark	Bill Sutherland	PT Cut	Buy	$35→$30

Analyst Ratings News

PRO
UBS Downgrades Surgery Partners to Neutral, Raises Price Target to $23.5

UBS analyst A.J. Rice downgrades Surgery Partners (NASDAQ:SGRY) from Buy to Neutral and raises the price target from $21 to $23.5.

Benzinga Newsdesk

PRO
StoneX Downgrades Surgery Partners to Hold

StoneX analyst Bill Sutherland downgrades Surgery Partners (NASDAQ:SGRY) from Buy to Hold.

Benzinga Newsdesk

PRO
RBC Capital Reiterates Outperform on Surgery Partners, Maintains $19 Price Target

RBC Capital analyst Ben Hendrix reiterates Surgery Partners (NASDAQ:SGRY) with a Outperform and maintains $19 price target.

Benzinga Newsdesk

PRO
TD Cowen Reiterates Buy on Surgery Partners, Maintains $19 Price Target

TD Cowen analyst Ryan Langston reiterates Surgery Partners (NASDAQ:SGRY) with a Buy and maintains $19 price target.

Benzinga Newsdesk

PRO
JP Morgan Maintains Neutral on Surgery Partners, Raises Price Target to $15

JP Morgan analyst Benjamin Rossi maintains Surgery Partners (NASDAQ:SGRY) with a Neutral and raises the price target from $14 to $15.

Benzinga Newsdesk

PRO
TD Cowen Maintains Buy on Surgery Partners, Raises Price Target to $19

TD Cowen analyst Ryan Langston maintains Surgery Partners (NASDAQ:SGRY) with a Buy and raises the price target from $17 to $19.

Benzinga Newsdesk